Drug Profile

PB 101 - PlateletBio

Alternative Names: PB-101 - PlateletBio

Latest Information Update: 28 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PlateletBio
Class Cell therapies; Gene therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Idiopathic thrombocytopenic purpura

Most Recent Events

28 Dec 2025 No recent reports of development identified for research development in Idiopathic thrombocytopenic purpura in USA (Parenteral)
11 Feb 2022 PlateletBio announces intention to submit IND for Immune thrombocytopenia in the first half of 2022 (PlateletBio pipeline, February 2022)
05 Nov 2021 PlateletBio announces intention to submit IND application for Idiopathic thrombocytopenic purpura

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com